Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3319481
Max Phase: Preclinical
Molecular Formula: C31H46N4O7
Molecular Weight: 586.73
Molecule Type: Small molecule
Associated Items:
ID: ALA3319481
Max Phase: Preclinical
Molecular Formula: C31H46N4O7
Molecular Weight: 586.73
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)[C@@]2(C)CO2)cc1
Standard InChI: InChI=1S/C31H46N4O7/c1-21(32-27(36)19-35-13-15-41-16-14-35)29(38)34-26(18-23-9-11-24(40-3)12-10-23)30(39)33-25(28(37)31(2)20-42-31)17-22-7-5-4-6-8-22/h9-12,21-22,25-26H,4-8,13-20H2,1-3H3,(H,32,36)(H,33,39)(H,34,38)/t21-,25-,26-,31+/m0/s1
Standard InChI Key: UHNYITHLNFUAIN-VTNASVEKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 586.73 | Molecular Weight (Monoisotopic): 586.3366 | AlogP: 1.37 | #Rotatable Bonds: 14 |
Polar Surface Area: 138.60 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.86 | CX Basic pKa: 5.04 | CX LogP: 2.09 | CX LogD: 2.09 |
Aromatic Rings: 1 | Heavy Atoms: 42 | QED Weighted: 0.28 | Np Likeness Score: -0.35 |
1. de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS.. (2014) Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes., 57 (14): [PMID:25006746] [10.1021/jm500716s] |
Source(1):